| Type | Public company |
|---|---|
| LSE: RENE | |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
| Website | reneuron.com |
ReNeuron is a UK-based stem cell research company whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
ReNeuron is testing the effects of neural stem cells on spinal cords for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
References
- ↑ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ↑ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.